CCR5 and neoplasm: Although the CCR5 antagonist MVC alone did not significantly reduce tumor volume, combined treatment with Bortezomib led to significant tumor shrinkage, supported by a synergistic effect between CCR5 antagonists and chemotherapy in inhibiting tumor proliferation and promoting apoptosis.